Neither the Q3 2022 Earnings Call presentation (2/11/2020), nor the J P Morgan presentation (10/1/23) make reference to the investigational drug status of either trofinetide or ACP- 204 in their pipeline slides.
The pipeline slide you provided was from the Acadia website pipeline page.
On this page, it is specifically stated
Our pipeline information may include a reference to an investigational agent or an investigational use of the FDA approved product. Safety and efficacy for investigational uses or agents have not been established or approved by the FDA. This table provides an overview of selected projects in development and can be filtered by both therapeutic area and development phase.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)